An allergic reaction regrew hair, and the cytokines everyone would blame were not involved

Design

preclinical - spatial transcriptomics and single-cell RNA sequencing in a mouse contact hypersensitivity model

Population

mice undergoing contact hypersensitivity-induced hair regeneration

Primary outcome

immune cell remodelling and the signalling pathway driving hair follicle stem cell proliferation

Effect

shift towards CD14+SPP1+ macrophages; SPP1 engaged CD44 on hair follicle stem cells activating PI3K-AKT; TNF-α and IL-1 signalling dispensable

That contact hypersensitivity induces hair growth is an old observation - it underlies the use of diphencyprone and squaric acid dibutyl ester as contact immunotherapy in alopecia areata, a treatment used for decades without anyone knowing how it works. This study mapped the process in mice using spatial transcriptomics and single-cell RNA sequencing.

Macrophages were the cell population that changed most. Five transcriptionally distinct subsets were resolved, and contact hypersensitivity drove a shift from homeostatic antigen-presenting macrophages towards a pro-inflammatory CD14-positive, SPP1-positive population. Those cells secreted SPP1 - osteopontin - which bound CD44 on hair follicle stem cells, activating PI3K-AKT signalling and driving their proliferation. Trajectory analysis showed the differentiation paths diverging between homeostatic and allergic conditions.

The negative result is the interesting one: signalling through TNF-α and IL-1, the cytokines a clinician would assume were responsible for an inflammation-driven effect, was dispensable. That has a practical implication if it holds in humans - it suggests the hair regrowth from contact immunotherapy could in principle be separated from the inflammation that makes the treatment unpleasant, and that a patient on a TNF inhibitor for another indication would not necessarily lose the effect. Both are hypotheses. This is mouse work, and contact immunotherapy in alopecia areata remains an empirical treatment delivered by dermatologists who have done it for years.

• Contact immunotherapy for alopecia areata is unchanged by this - continue as you do
• Do not offer or attribute hair regrowth to allergic contact dermatitis from any other source
• Note the practical hypothesis: the regrowth signal may be separable from the inflammation, which would be a better treatment if confirmed
• Keep counselling patients that contact immunotherapy response rates are variable and relapse on stopping is common
• Treat SPP1-CD44 as a research target, not a test or a treatment

Why it matters

A treatment dermatologists have used for decades without a mechanism now has one, and it is not the one anyone assumed.

Don't overread it

Mouse work - the SPP1-CD44 axis has not been shown to operate in human alopecia areata.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.